Literature DB >> 8044786

Comparative Gompertzian analysis of alterations of tumor growth patterns.

I D Bassukas1.   

Abstract

We have shown previously that different patterns of growth (including classical Gompertzian, exponential, and hyperexponential) can be described based on the Gompertzian difference equation, In G(t+s) = a+b In G(t) [G(t), tumor size at time t; s, constant time interval of a stroboscopic set of tumor size measurements], by the initial or intrinsic growth rate, a, and the exponential rate of growth deceleration, b (I. D. Bassukas and B. Maurer-Schultze, Growth Dev. Aging, 52: 113-122, 1988). Particularly, the possible effects of antineoplastic treatments on this latter factor have not been adequately appreciated to date. In the present study a new method of comparison of growth process is introduced, which consists of two steps. (a) The corresponding growth patterns are compared with each other on the basis of the Gompertzian difference equation using an analysis of variance algorithm. The result indicates whether or not there is an alteration of the growth pattern and, if there is one, whether it refers to alterations of the a and/or b values for the growth patterns. (b) The ultimate effect of any perturbation is assessed by using the limit (for t-->infinity) of the quotient of the tumor sizes after and before perturbation to characterize it as stimulation or inhibition. The present approach introduces a new quality of tumor growth perturbations; tumor growth may be altered although being neither inhibited nor stimulated, a phenomenon with biological significance still to be evaluated. The application of this method to the treatment with suramin of a human renal cell carcinoma xenograft in nude mice reveals a complex alteration of its growth pattern. Suramin simultaneously inhibits both the initial or intrinsic growth rate and the exponential rate of growth deceleration of this tumor. Consequently, this tumor starts with a lower growth rate in the presence of suramin; however, this rate also decelerates more slowly as a function of tumor growth, so that treated tumors, although initially inhibited, grow larger than controls.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044786

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Authors:  K S Tewari; J J Java; R N Eskander; B J Monk; R A Burger
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

2.  Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model.

Authors:  L Possati; D Campioni; F Sola; L Leone; L Ferrante; C Trabanelli; M Ciomei; M Montesi; R Rocchetti; S Talevi; S Bompadre; A Caputo; G Barbanti-Brodano; A Corallini
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

3.  Chemotherapy in conjoint aging-tumor systems: some simple models for addressing coupled aging-cancer dynamics.

Authors:  Mitra S Feizabadi; Tarynn M Witten
Journal:  Theor Biol Med Model       Date:  2010-06-15       Impact factor: 2.432

4.  Modified leaky competing accumulator model of decision making with multiple alternatives: the Lie-algebraic approach.

Authors:  Chi-Fai Lo; Ho-Yan Ip
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

5.  Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.

Authors:  Gary Mo; Frank Gibbons; Patricia Schroeder; Wojciech Krzyzanski
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

6.  Mathematical model of hormone sensitive prostate cancer treatment using leuprolide: A small step towards personalization.

Authors:  Urszula Foryś; Alon Nahshony; Moran Elishmereni
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

7.  A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies.

Authors:  Benjamin Ribba; Thierry Colin; Santiago Schnell
Journal:  Theor Biol Med Model       Date:  2006-02-10       Impact factor: 2.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.